Patrick Boland

GI Medical Oncologist @RutgersCancerInstNJ
Dad, husband, music enthusiast, amateur pianist #crcsm #colorectal cancer

[Ronan Hsieh, MD, MS @ronanhsieh]

Also to add that PFS1 and PFS2 were both significantly higher in EGFRi vs Avastin in 1L (SEQ1 vs SEQ2) and 2L (SEQ2 vs SEQ1). But no overall PFS difference. OS is immature.

This is the opposite of PARADIGM study. In PARADIGM, 1L EGFRi led to significant OS benefits but no PFS benefits. Criticism of the trial includes fewer patients receiving 2L+ EGFRi in the control arm.

My take in this? For mCRC, we just need to give all the drugs to patients, regardless of lines. But it is best to give EGFRi in 1L, given better response and PFS1. Some patients might not be able to get it 2L.

[Arndt Vogel @ArndtVogel]

Onvansertib plus SOC CTx plus bevacizumab in first-line RAS-mutated mCRC: Interim results from the phase 2 randomized CRDF-004 trial
#ASCO26
👉oral PLK1 inhibitor
👉promising efficacy
👉safety manageable
@myesmo @ASCO

[Arndt Vogel @ArndtVogel]

ctDNA clearance as an early indicator of sotorasib +
panitumumab efficacy and prognosis in KRAS
G12C–mCRC: Results from phase 3 CodeBreaK 300
#ASCO26
👉ctDNA clearance = early biomarker for response
👉significantly higher with sotorasib
🧐could be useful in the clinic
@myesmo @ASCO

[Kohei shitara @KoheiShitara]

Pleased to report randomized phase 2 of EP4 inhibitor ONO-4578 plus nivolumab and chemo for HER2-negative gastric/GEJ cancer in @JCO, concurrently at #ASCO2026 @ASCO. ONO-4578 improved PFS (HR 0.67) and showed encouraging OS (HR 0.60), warranting phase 3.https://t.co/fLhukoRKu6

[Arndt Vogel @ArndtVogel]

Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for 1l CTx intensification in mCRC and validation in prospective randomized phase III trials
#ASCO26
👉interesting & promising approach, could be highly useful
@myesmo @ASCO

[Clinical Cancer Research @CCR_AACR]

Now online: Molecular Lineages of Sporadic Mismatch Repair–Deficient Colorectal Cancer https://t.co/SMeahFDRcY

[Rutgers Cancer Institute @RutgersCancer]

.@RutgersCancer @RWJBarnabas Dr. Patrick Boland @PMBolandMD presents “Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).” at #ASCO26.
https://t.co/rUhOx2xbZy

@ASCO

[Rutgers Cancer Institute @RutgersCancer]

.@RutgersCancer @RWJBarnabas Dr. Patrick Boland @PMBolandMD presents “Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.” at #ASCO26.
https://t.co/YaZUuxIknV

@ASCO

[Patrick Boland @PMBolandMD]

@Deebacca @christianacare @Sarbaji85064063 Congrats!

[Nicholas Hornstein @GIMedOnc]

RevMed with huge news for pancreatic cancer (daraxonrasib).

The headline is hard to ignore 👀

• Median OS 13.2 vs 6.7 months
• HR ~0.4 📉
• Activity across KRAS variants (not just G12C)
• Manageable safety

If that signal is real, this isn’t incremental. It changes how we think about KRAS.

But—caveat applies ⚠️
This is a press release! PR as a rule is rosier than real data.

Still… an OS HR like that gets your attention.

Feels like we may be moving from mutation-specific inhibition → broader KRAS control.

That’s the difference between niche utility and something that touches CRC, pancreas, lung… everything we see.

Now we wait for the data behind the headline.

@TheGutOncLab @OncoAlert @Onco_Nexus

https://t.co/MBsxalyQT3

[Syed A. Ahmad @SyedAAhmad5]

Neoantigen evolution and response to checkpoint inhibitor immunotherapy in colorectal cancer ⁦@NaturePortfolio⁩ https://t.co/QHYxFf9jhA

[Max Kozlov @maxdkozlov]

Congress rejected massive cuts to US science budgets for 2026, but much of the money still isn’t flowing to researchers.

The culprit? The White House Office of Management and Budget (OMB) is quietly slow-walking the release of funds. 🧵👇

For @Nature:
https://t.co/cvO5Q8HGcl

[JAMA Oncology @JAMAOnc]

Immune checkpoint inhibitor–induced #diabetes occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with #chemotherapy. https://t.co/tBiG2pfgDy

[Journal of Clinical Oncology @JCO_ASCO]

Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe.

Read the full article. https://t.co/NNOIfnqSHd

[NBC News @NBCNews]

Colorectal cancer is now the leading cause of cancer deaths among people younger than 50 in the United States, according to a study. https://t.co/yjPAdewfUk

[Eric Topol @EricTopol]

Colon cancer is now the leading cause of cancer deaths in Americans under age 50, and 75% are diagnosed at late stages, by @betswrites
gift link https://t.co/uRBxPBjf6C

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

Immunological Dynamics in Rectal Cancer: SCRT vs LCRT @CCR_AACR
◾️Circulating lymphocytes: SCRT (less depletion) > LCRT
◾️Immune cells in TME: SCRT (higher density of CD8+ & FOXP3+) > LCRT, no diff. in FOXP3/CD8 ratio
👉SCRT is potentially preferred backbone in combination with ICIs

https://t.co/93KYlTezIA
@OncoAlert @C_Roxburgh

[Oncology Brothers @OncBrothers]

Rx in R/R metastatic colorectal cancer, outside trials, if there is no 🎯mutations, are limited! Dose optimization is important!

1. Biweekly dosing for TAS102 by @CathyEngMD @ChrisMCann et al

2. ReDOS Regorafenib dosing by @GIcancerDoc et al

3. Fruquintinib 5mg: 21 on/7 off

[Riya Patel, MD @patel_riya7]

Congratulations to Dr. Iyer on becoming the new CMO of the @NCCN!
Having learned so much under her guidance, I’m beyond grateful for her mentorship, kindness, and example of what true leadership looks like.

A real #BossLady changing the future of cancer care.
@WomenInOncology

[Dr. jordan berlin @jordanberlin5]

In 2024, Elsevier publishers, parent company of @sciencedirect reported profits of over 3 Billion pounds and @SpringerNature reported over 1.8 billion pounds of profit. All off the work we do for them for free. Hey publishers, pay for reviews.